ENTITY
Bristol Myers Squibb Co

Bristol Myers Squibb Co (BMY US)

230
Analysis
Health Care • United States
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
more
bearish•Cross Asset Strategy
•09 Oct 2015 02:02

Many (un)happy returns in EM; governance and the vicious circle

This report examines the underlying governance factors that have driven EM underperformance over the last five years.Brazil, Russia, Malaysia and...

Share
•07 Oct 2015 11:15

Morningstar Healthcare Observer: Biotech Industry Undervalued

The median price/fair value in our biotech universe is 0.87, and in late September valuations fell to their cheapest levels since 2011. While this...

Share
•06 Oct 2015 11:03

SoulCycle IPO - Good for your portfolio and your soul?

"Dance party on a bike" - that's how the founders of SoulCycle like to describe their business. SoulCycle is a lifestyle and fitness brand that...

Logo
342 Views
Share
•29 Sep 2015 10:12

U.S. Economy Picks up the Pace: We're bumping up our 2015 GDP forecast

Growth in the second quarter was revised up from 3.7% to 3.9%, beating the consensus estimate of 3.7% growth.It was what economists like to call a...

Share
•14 Sep 2015 14:26

CORPORATE LEVERAGE: An Inconvenient Truth

Sometimes stock markets don’t bounce back. They just hit the bottom and then crawl sideways for years. Take Greece, its stock market is still 87%...

Logo
410 Views
Share
x